All GLP-1 medications from licensed 503A compounding pharmacies Browse Products

Originally posted by @drmichaelsays on TikTok · 84s|Watch on TikTok
Full video transcriptClick to expand

Auto-generated transcript of @drmichaelsays's video. Quoted here for educational fact-check commentary; original creator retains all rights to the video content.

  1. 0:00There are six types of peptides out there, have you heard of all them?
  2. 0:03Number one, you will have heard of them, insulin memetics, GLP1, GIP, and glucagon.
  3. 0:09Sculman would be Ozempic, Mingero, Baba-Baba.
  4. 0:12Number two, copper peptides, probably heard of GHK-Cu,
  5. 0:15stimulates collagen and skin remodeling.
  6. 0:18Number three is growth hormone secretigogs.
  7. 0:20The short-acting ones, there's long-acting ones, there's sirmaryllin, the pamaryllin,
  8. 0:24CGC1295, and these basically simulate growth hormone from your pituitary gland and
  9. 0:29increase IGF-1, which can have its problems.
  10. 0:31The next is cyto-protective peptides.
  11. 0:33So these are the peptides that interfere with the nitric oxide pathways, like BPC-157,
  12. 0:38we do the most famous one.
  13. 0:39Those stimulate angiogenesis and soft tissue repair.
  14. 0:42You've got melanocortinin agonists, so that's things like melanatin.
  15. 0:46Two wouldn't recommend, lots of people are doing it.
  16. 0:48And this is a really interesting subgroup called mitochondrial derived peptide.
  17. 0:52Just work on the AMPK pathway in your mitochondria.
  18. 0:55It's a powerhouse of the cell, remember.
  19. 0:57That regulates energy metabolism and angel insensitivity.
  20. 1:00Most common peptide you've heard from that one is mo-c.
  21. 1:03And yeah, like it's an exciting space, but they're all unregulated, they're all untested,
  22. 1:08apart from the ones that we use for weight loss and diabetes.
  23. 1:10People are using them, so if you're gonna do it, you do your research and you make sure what
  24. 1:15you're getting is legit, because it is the Wild West out there.
  25. 1:18Influencers who are selling them are gonna tell you a lot of shit.
  26. 1:22Stay safe.

@drmichaelsays's peptide therapy claims need more evidence

Doctor Michael

TikTok creator

22.6K viewsWatch on TikTok

Quick answer

The creator covers six peptide categories with varying clinical evidence bases, from FDA-approved GLP-1 receptor agonists with robust phase 3 trial data to mitochondrial-derived peptides like MOTS-c that remain largely confined to preclinical and early human aging studies. BPC-157 and growth hormone secretagogues like CJC-1295 occupy a middle ground with plausible mechanisms but no completed randomized controlled trials in humans supporting efficacy claims. The FDA's 2023 decision to restrict BPC-157 from compounding reflects the regulatory reality that "exciting" mechanistic data does not equal clinical approval.

Video review standard

Clinical fact-check snapshot

FormBlends treats social health videos as a starting point, then checks the claim against medical context, source quality, safety limits, and whether licensed provider review belongs in the next step.

Peptide social video fact-checksMedical claim reviewProvider discussion

Evidence signal

Source-backed review

Regulatory reality

Access rules depend on the compound and patient situation

Safety screen

Viral claims can miss contraindications, dose escalation, medication interactions, and quality-control risks.

This page currently connects to 8 source-backed evidence items through visible references or structured citation data.

PubMed evidence trail

Research sources used to frame this page

For @drmichaelsays's peptide therapy claims need more evidence, FormBlends checks the page topic against primary trials, systematic reviews, guidelines, and current PubMed-indexed literature where available. These citations are context, not medical advice, proof of eligibility, or a claim that every study applies to every patient.

Provider decision path

Use local research to choose a safer review path

Direct answer

@drmichaelsays's peptide therapy claims need more evidence is best used to compare access, oversight, pricing, pharmacy quality, and patient support before starting care.

Evidence check

Directory pages should connect local intent with provider standards, pharmacy transparency, and practical next steps.

Safety check

Provider quality, pharmacy source, prescribing model, and follow-up support can matter as much as the medication name.

Next step

When you are ready, the get-started flow can collect the details needed for a prescription review instead of leaving you to guess.

Page-specific review note

What this exact clip is really saying

This FormBlends review is specific to "@drmichaelsays's peptide therapy claims need more evidence" from Doctor Michael. We read the clip as a Peptide social video fact-checks claim about Peptide social video fact-checks, then separate the useful signal from what a short social video cannot prove. The page-specific claim focus is: The creator covers six peptide categories with varying clinical evidence bases, from FDA-approved GLP-1 receptor agonists with robust phase 3 trial data to mitochondrial-derived peptides like MOTS-c that remain largely confined to preclinical and early human aging studies.

The reason this review is not generic is the source wording and the canonical claim label "peptides tiktok 7611876329893465351." In this clip, the useful excerpt is: "There are six types of peptides out there, have you heard of all them?" That wording changes the review because it points to Peptide social video fact-checks evidence, safety, and patient-fit context, not a one-size-fits-all protocol.

The source trail for this page is checked against Once-Weekly Semaglutide in Adults with Overweight or Obesity (2021), Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance (2021), and Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight (2022), plus the creator's own wording. Peptide social video fact-checks decisions still need an eligibility review, medication-interaction screen, access check, and quality-control review before anyone treats a social clip as medical advice.

BPC-157's mechanistic data comes almost entirely from rodent studies; the FDA restricted it from compounding formulations in 2023, which the video does not mention.
People who land here are usually trying to understand whether the Peptide social video fact-checks claim is evidence-backed, safe, and relevant to their own situation.
The strongest next step is to compare the claim with FormBlends' Peptide social video fact-checks guide, evidence notes, and provider review path before acting.

Claim verdict

The useful answer behind this video

This page is built to answer the specific claim behind the clip, then separate what is useful from what still needs clinical context. That makes the URL more than a repost: it gives Google, readers, and AI retrieval systems a concise verdict with source and safety boundaries.

Claim being checked

The creator covers six peptide categories with varying clinical evidence bases, from FDA-approved GLP-1 receptor agonists with robust phase 3 trial data to mitochondrial-derived peptides like MOTS-c that remain largely confined to preclinical and early human aging studies.

FormBlends verdict

Peptide social video fact-checks evidence, safety, and patient-fit context

Evidence strength

Source-backed review with clinical or regulatory citations.

Patient-safe next step

Compare the claim with FormBlends safety guidance and a licensed-provider review before acting.

What to do with this video

Use the clip as a claim to verify, not a treatment plan

What it helps with

  • The creator covers six peptide categories with varying clinical evidence bases, from FDA-approved GLP-1 receptor agonists with robust phase 3 trial data to mitochondrial-derived peptides like MOTS-c that remain largely confined to preclinical and early human aging studies. BPC-157 and growth hormone secretagogues like CJC-1295 occupy a middle ground with plausible mechanisms but no completed randomized controlled trials in humans supporting efficacy claims. The FDA's 2023 decision to restrict BPC-157 from compounding reflects the regulatory reality that "exciting" mechanistic data does not equal clinical approval.
  • GLP-1 receptor agonists like semaglutide are the only peptides in this video with FDA approval and phase 3 randomized trial support for efficacy and safety.
  • BPC-157's mechanistic data comes almost entirely from rodent studies; the FDA restricted it from compounding formulations in 2023, which the video does not mention.

What it may miss

  • It may not cover eligibility, contraindications, medication interactions, lab history, or dose escalation.
  • Compound access, legal status, and product quality still need a separate safety check.
  • Social video captions rarely show the full evidence base behind a claim.

Best next step

Compare the claim against a FormBlends guide, safety page, and licensed-provider review before acting.

Start provider review

What You'll Learn

  • GLP-1 receptor agonists like semaglutide are the only peptides in this video with FDA approval and phase 3 randomized trial support for efficacy and safety.
  • BPC-157's mechanistic data comes almost entirely from rodent studies; the FDA restricted it from compounding formulations in 2023, which the video does not mention.
  • MK-677 is a growth hormone secretagogue, not a mitochondrial-derived peptide. The creator misclassified it, which matters if you are trying to understand what category of compound you are researching.
  • Melanotan II has documented risks including cardiovascular effects and case reports linking it to melanoma progression (Cosgarea et al., 2020, JAMA Dermatology). The creator's reluctance to recommend it is the right call.
  • MOTS-c is the primary mitochondrial-derived peptide studied for AMPK pathway regulation and insulin sensitivity, per Lee et al. (2015, Cell Metabolism), not MK-677.
  • CJC-1295 is a GHRH analogue; ipamorelin is a ghrelin receptor agonist. They work through different receptors and are often stacked, but they are not the same class of secretagogue.
  • The creator's sourcing warning is the most actionable advice in the video: peptide supply chain integrity is a documented problem, and purity verification through certificate of analysis from an independent lab is the minimum standard before anyone considers use.

Our take · Written by FormBlends editorial team · Reviewed by FormBlends Medical Team · This is not a transcript. It is our independent review of the video above.

What did @drmichaelsays actually say?

The creator ran through six peptide categories in a single TikTok: insulin mimetics (GLP-1s, GIP, glucagon), copper peptides like GHK-Cu, growth hormone secretagogues (including CJC-1295 and what they called "sirmaryllin" and "pamaryllin"), cytoprotective peptides like BPC-157, melanocortin agonists like melanotan II, and mitochondrial-derived peptides working through the AMPK pathway. They closed with a blunt disclaimer: peptides outside the weight-loss and diabetes category are "unregulated" and "untested," and influencers selling them "are gonna tell you a lot of shit."

The video is genuinely more honest than most peptide content on TikTok. That said, several classification choices and mechanism descriptions are imprecise enough to matter, and at least one category gets mislabeled in a way that could mislead someone trying to do actual research.

Does the science back this up?

Mostly, but with real gaps. The GLP-1 receptor agonist classification is solid, the GHK-Cu collagen claim is supported by human cell and animal data, and the growth hormone secretagogue category is real and well-characterized. The AMPK-mitochondria framing for mitochondrial-derived peptides is directionally correct.

Where it gets shakier is BPC-157. Calling it a "cytoprotective peptide" that works through nitric oxide pathways is a partial picture at best. BPC-157's proposed mechanisms include modulation of the NO system, but also involve the VEGF pathway, FAK-paxillin signaling, and interaction with growth hormone receptors, according to Sikiric et al. (2018, Current Pharmaceutical Design). Framing it narrowly as a nitric oxide peptide understates how poorly understood its full mechanism actually is in humans, since the bulk of mechanistic data comes from rodent models. A viewer could walk away thinking BPC-157's mechanism is settled science. It is not.

What did they get wrong (or right)?

Credit where it is due: the warning about melanotan II is correct and overdue. The creator says they "wouldn't recommend" it, which is the right call. Melanotan II is a non-selective melanocortin receptor agonist with documented risks including nausea, spontaneous erections, and reported associations with melanoma progression in case studies (Cosgarea et al., 2020, JAMA Dermatology). The creator should have been more forceful here, but at least they flagged it.

The category name "cytoprotective" for BPC-157 is also a reasonable clinical shorthand used in some of the original Croatian research. That is fair.

What they got wrong: CJC-1295 is a GHRH analogue, not a ghrelin mimetic. Grouping it in the same breath as ipamorelin (a ghrelin receptor agonist) without distinguishing the two mechanisms is a meaningful error for anyone trying to understand how these compounds differ pharmacologically. They also listed "MK-677" under the mitochondrial-derived peptide category, calling it the most common peptide in that group. MK-677 (ibutamoren) is actually a growth hormone secretagogue and belongs in the prior category, not with mitochondrial peptides like humanin or MOTS-c. That is a factual misclassification.

What should you actually know?

The creator's closing statement is the most accurate thing in the video: outside of approved GLP-1 drugs like semaglutide, these peptides are largely untested in controlled human trials. That is not a minor caveat. It means efficacy claims, dosing assumptions, and safety profiles for most of what gets sold online are built almost entirely on animal studies and anecdote.

The regulatory picture is also more specific than "unregulated" suggests. In the US, many research peptides are sold legally as "not for human use" lab reagents. Some, like BPC-157 and CJC-1295, have been on FDA compounding restriction lists. The FDA placed BPC-157 on its list of bulk drug substances that may not be compounded in 2023. That is a material fact the video omits entirely.

  • If you are considering any of these compounds, the starting point is a licensed provider with actual lab access, not a TikTok comment section or a grey-market research chemical website.
  • "Doing your research" on unregulated peptides means reading primary literature, not Reddit threads.

The bottom line

This video is better than average for TikTok peptide content. The creator does not hype miracle outcomes, they warn about melanotan II, and they tell viewers to verify sourcing. But the MK-677 misclassification is real, the BPC-157 mechanism is oversimplified, and the regulatory nuance around compounding is missing entirely. Treat this as a rough orientation to the space, not a clinical reference.

Interested in GLP-1 or peptide therapy?

Get matched with licensed-provider review to help decide if it is right for you.

Free Assessment

About the Creator

Doctor Michael · TikTok creator

22.6K views on this video

@drmichaelsays's peptide therapy claims need more evidence

Frequently asked questions

Quick answers based on this video and our medical team review.

What does the video say about glp-1 receptor agonists like semaglutide?

GLP-1 receptor agonists like semaglutide are the only peptides in this video with FDA approval and phase 3 randomized trial support for efficacy and safety.

What does the video say about bpc-157's mechanistic data comes almost entirely from rodent studies; the?

BPC-157's mechanistic data comes almost entirely from rodent studies; the FDA restricted it from compounding formulations in 2023, which the video does not mention.

What does the video say about mk-677?

MK-677 is a growth hormone secretagogue, not a mitochondrial-derived peptide. The creator misclassified it, which matters if you are trying to understand what category of compound you are researching.

What does the video say about melanotan ii has documented risks including cardiovascular effects?

Melanotan II has documented risks including cardiovascular effects and case reports linking it to melanoma progression (Cosgarea et al., 2020, JAMA Dermatology). The creator's reluctance to recommend it is the right call.

What does the video say about mots-c?

MOTS-c is the primary mitochondrial-derived peptide studied for AMPK pathway regulation and insulin sensitivity, per Lee et al. (2015, Cell Metabolism), not MK-677.

What does the video say about cjc-1295?

CJC-1295 is a GHRH analogue; ipamorelin is a ghrelin receptor agonist. They work through different receptors and are often stacked, but they are not the same class of secretagogue.

Sources & references

Citations extracted from our medical team's review. Click any citation to search PubMed.

Educational use only. This fact-check is editorial content for general information. Nothing here is medical advice. Talk to a licensed provider about your specific situation before starting, stopping, or changing any supplement, peptide, or medication regimen.

Read More on This Topic

Our written guides go deeper with dosing details, comparison tables, and medical-team reviewed protocols.

Not medical advice. This video was made by Doctor Michael, not by FormBlends. Our write-up above is an editorial review, not a medical recommendation. Talk to your doctor before making any decisions about medications or treatments.